Clinical trial
Comparison of Hylastan to Methylprednisolone Acetate in Patients With…
NCT00139295 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00139295 |
|---|---|
| Title | Comparison of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee |
| Official title | Comparison of the Efficacy and Safety of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoarthritis, Knee |
| Intervention type | Device |
| Interventions | Hylastan |
| Start date | Oct 1, 2004 |
| Completion | Sep 1, 2007 |
| First posted | Aug 31, 2005 |
| Last update posted | Feb 5, 2014 |
| Countries | Canada, France, Germany, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: